Tigermed completes acquisition of Japan-based Micron

HANGZHOU/TOKYO - Tigermed (300347.SZ/3347.HK), a prominent player in the Life Sciences Tools & Services industry with a market capitalization of $8.2 billion, announced Tuesday it has completed the acquisition of Japan-based Contract Research Organization (CRO) Micron, Inc. The company’s stock has shown remarkable momentum, gaining nearly 30% over the past six months, according to InvestingPro data.

Founded in 2005 and headquartered in Tokyo, Micron specializes in medical imaging and clinical trial services with over 160 employees. The company has served more than 250 clients and contributed to the approval of over 40 drugs during its nearly two decades of operation. Tigermed maintains a solid financial foundation with a healthy current ratio of 1.62 and moderate debt levels, as revealed by InvestingPro analysis.

Following the acquisition, Micron will be integrated into Tigermed’s global network as a key entity under Tigermed Japan. The deal aims to enhance Tigermed’s coverage across Japan and the Asia-Pacific region in medical imaging capabilities.

"Micron’s unique strengths in technology and proven track record will be of great value to Tigermed’s business expansion in Japan and Asia-Pacific region," said Michael Wen, Co-President of Tigermed, in the press release statement.

Hiroaki Suzuki, President and Co-founder of Micron, stated, "We believe our 20 years of medical imaging experience and expertise will become a strong support to Tigermed in this sector."

As the first imaging CRO in Japan, Micron has established itself in imaging biomarkers and AI-powered imaging support. The company operates offices in Tokyo, Osaka, and Nagoya, providing services including monitoring, quality control, imaging core lab operations, and image analysis.

Tigermed currently operates in more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America, and Africa. Financial terms of the acquisition were not disclosed in the announcement. With projected net income growth and 12 additional valuable insights available on InvestingPro, investors can gain deeper understanding of Tigermed’s financial outlook and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.